Back to Search
DIVYA CHAUHAN, MD
MD
Allergy & Immunology Physician
NPI: 1487920658IndividualAccepts Medicare
Specialties, Licenses & Credentials
Allergy & Immunology PhysicianPrimary
Allergy & Immunology
Code: 207K00000X
10327985-1205(UT)59739(CO)
Pediatric Allergy/Immunology Physician
Pediatrics — Pediatric Allergy/Immunology
Code: 2080P0201X
10327985-1205(UT)
CMS Specialties
PrimaryPEDIATRIC MEDICINE
Education
UNIVERSITY OF UTAH SCHOOL OF MEDICINE
Class of 2015
Research & Publications (20)
Factors affecting the uptake of new medicines in secondary care - a literature review.
PMID 18613851·J Clin Pharm Ther·2008
6-review
Highly enhanced adsorption for decontamination of lead ions from battery wastewaters using chitosan functionalized with xanthate.
PMID 18490156·Bioresour Technol·2008
8-other
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
PMID 18006697·Blood·2008
7-preclinical
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
PMID 17032924·Blood·2007
7-preclinical
Molecular typing of Mycobacterium tuberculosis isolates from different parts of India based on IS6110 element polymorphism using RFLP analysis.
PMID 17598945·Indian J Med Res·2007
8-other
Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups.
PMID 17234022·Int J Technol Assess Health Care·2007
8-other
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
PMID 17016430·Oncogene·2007
8-other
A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
PMID 17047643·Br J Cancer·2006
6-review
Failure of prophylactic retinopexy in fellow eyes without a posterior vitreous detachment.
PMID 16832019·Arch Ophthalmol·2006
8-other
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
PMID 16286248·Cancer Cell·2005
4-observational
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
PMID 16166312·Cancer Res·2005
8-other
Proteasome inhibition in multiple myeloma: therapeutic implication.
PMID 15822185·Annu Rev Pharmacol Toxicol·2005
6-review
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
PMID 15094775·Oncogene·2004
8-other
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
PMID 15070698·Blood·2004
8-other
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
PMID 15004512·Apoptosis·2004
8-other
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
PMID 14559800·Cancer Res·2003
8-other
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
PMID 13679868·Oncogene·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1400 JACKSON ST
DENVER, CO 80206 - Phone
- (303) 388-4461
Quick Facts
- NPI
- 1487920658
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile